keyword
MENU ▼
Read by QxMD icon Read
search

NCCN

keyword
https://www.readbyqxmd.com/read/28094250/end-of-radiation-psa-as-a-novel-prognostic-factor-in-patients-undergoing-definitive-radiation-and-androgen-deprivation-therapy-for-prostate-cancer
#1
A K Narang, J Trieu, N Radwan, A Ram, S P Robertson, P He, C Gergis, E Griffith, H Singh, T A DeWeese, S Honig, A Annadanam, S Greco, C DeVille, T McNutt, T L DeWeese, D Y Song, P T Tran
BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993 to 2006 and who had an end-of-radiation (EOR) PSA (n=688, median follow-up 11.2 years). We analyzed the association of an EOR PSA level, obtained during the last week of radiation, with survival outcomes...
January 17, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28093788/north-american-population-based-validation-of-the-national-comprehensive-cancer-network-practice-guideline-recommendation-of-pelvic-lymphadenectomy-in-contemporary-prostate-cancer
#2
Sami-Ramzi Leyh-Bannurah, Lars Budäus, Raisa Pompe, Emanuele Zaffuto, Alberto Briganti, Firas Abdollah, Francesco Montorsi, Jonas Schiffmann, Mani Menon, Shahrokh F Shariat, Margit Fisch, Felix Chun, Hartwig Huland, Markus Graefen, Pierre I Karakiewicz
BACKGROUND: National Comprehensive Cancer Network (NCCN) guidelines recommend a pelvic lymph node dissection (PLND) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) if a nomogram predicted risk of lymph node invasion (LNI) is ≥2%. We examined this and other thresholds, including nomogram validation. METHODS: We examined records of 26,713 patients treated with RP and PLND between 2010 and 2013, within the Surveillance, Epidemiology, and End Results database...
January 17, 2017: Prostate
https://www.readbyqxmd.com/read/28070166/biochemical-recurrence-prediction-in-high-risk-prostate-cancer-patients-following-robot-assisted-radical-prostatectomy
#3
Noriya Yamaguchi, Tetsuya Yumioka, Hideto Iwamoto, Toshihiko Masago, Shuichi Morizane, Masashi Honda, Takehiro Sejima, Atsushi Takenaka
BACKGROUND: High-risk prostate cancer treatment has been controversial. Some high-risk prostate cancer patients fail to respond to radical prostatectomy only. Thus, we aimed to investigate the predictive factors for biochemical recurrence (BCR) and identify patients who could achieve sufficient therapeutic effect by radical prostatectomy only. METHODS: Of 264 medical records reviewed, 141 low-intermediate-risk and 100 high-risk prostate cancer patients, excluding those who had received neoadjuvant hormone therapy, were analyzed...
December 2016: Yonago Acta Medica
https://www.readbyqxmd.com/read/28061904/classifying-high-risk-versus-very-high-risk-prostate-cancer-is-it-relevant-to-outcomes-of-conformal-radiotherapy-and-androgen-deprivation
#4
Akram Saad, Jeffrey Goldstein, Yaacov R Lawrence, Benjamin Spieler, Raya Leibowitz-Amit, Raanan Berger, Tima Davidson, Damien Urban, Lev Tsang, Dror Alezra, Ilana Weiss, Zvi Symon
OBJECTIVE: To evaluate outcomes in prostate cancer patients classified as high-risk (HR) or very high-risk (VHR) who were treated with conformal radiation therapy (CRT) and androgen deprivation therapy (ADT). METHODS: Between 11/2001 and 3/2012, 203 patients with HR disease received CRT to the prostate (78-82 Gy) and pelvic lymph nodes (46-50 Gy) with ADT (6 m-2 years). Median follow-up was 50 months (12 m-142 m). Biochemical failure was defined according to Phoenix definition...
January 6, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28058776/guideline-of-guidelines-non-muscle-invasive-bladder-cancer
#5
REVIEW
Solomon L Woldu, Aditya Bagrodia, Yair Lotan
Non-muscle invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, however this definition represents a spectrum of disease with a variable clinical course notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with a goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, however adherence to management principles amongt practicing urologists is reportedly low...
January 6, 2017: BJU International
https://www.readbyqxmd.com/read/28056253/-updates-and-interpretations-of-2017-nccn-guidelines-for-bone-cancer
#6
X H Niu
The NCCN guidelines for bone cancer are generally updated 1-2 times one year, the contents include diagnosis, treatment guidelines and the latest developments. The latest version of 2017 guideline of bone cancer is released recently. It includes multidisciplinary treatment of common primary bone cancer including diagnosis, surgery, drugs and radiotherapy. It covers osteosarcoma, chondrosarcoma, Ewing's sarcoma, giant cell tumor of bone and chordoma. In this article, the core contents and the updates are illustrated...
January 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/28056250/-outcome-evaluation-based-on-evidence-based-medicine-of-laparoscopic-surgery-for-rectal-cancer
#7
H W Yao, Y H Liu
Laparoscopic surgery of rectal cancer has experienced more than 20 years of technical development and clinical research. Based on the published high-level clinical trials such as COREAN, COLOR Ⅱ, ACOSOG Z6051 and ALacaRT, laparoscopic surgery is recommended as method to treat rectal cancer by the NCCN Clinical Practice Guideline on Rectal Cancer (version 1.2016) with class 2A evidence. But it is also suggested that the surgeons should have experiences of performing minimally invasive proctectomy with total mesorectal excision...
January 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/28045113/unscreened-older-men-diagnosed-with-prostate-cancer-are-at-increased-risk-of-aggressive-disease
#8
J J Tosoian, R Alam, C Gergis, A Narang, N Radwan, S Robertson, T McNutt, A E Ross, D Y Song, T L DeWeese, P T Tran, P C Walsh
BACKGROUND: To evaluate the relationship between PSA testing history and high-risk disease among older men diagnosed with prostate cancer. METHODS: Records from 1993 to 2014 were reviewed for men who underwent radiotherapy for prostate cancer at age 75 years or older. Patients were classified into one of four groups based on PSA-testing history: (1) no PSA testing; (2) incomplete/ineffective PSA testing; (3) PSA testing; or (4) cannot be determined. Outcomes of interest were National Comprehensive Cancer Network (NCCN) risk group (that is, low, intermediate or high risk) and biopsy grade at diagnosis...
January 3, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28040724/nccn-news
#9
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28040722/surgical-management-of-vulvar-cancer
#10
REVIEW
Thanh H Dellinger, Amy A Hakim, Stephen J Lee, Mark T Wakabayashi, Robert J Morgan, Ernest S Han
Vulvar cancer is a rare malignancy with high curability in early-stage disease, yet poor outcomes for advanced-stage and recurrent disease. Surgical management is at the cornerstone of treatment for most vulvar cancers, and includes conservative and radical resection of the primary vulvar tumor and excision of local lymph nodes, which are major prognostic factors and drive adjuvant treatment. This review summarizes the surgical management of primary squamous cell carcinoma of the vulva, specifically initial treatment guidelines by stage, based on the 2017 NCCN Clinical Practice Guidelines in Oncology for Vulvar Cancer...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28040721/vulvar-cancer-version-1-2017-nccn-clinical-practice-guidelines-in-oncology
#11
Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, Susana M Campos, Kathleen R Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S Dizon, Oliver Dorigo, Patricia J Eifel, Christine M Fisher, Peter Frederick, David K Gaffney, Ernest Han, Susan Higgins, Warner K Huh, John R Lurain, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W Remmenga, R Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A Valea, Emily Wyse, Catheryn M Yashar, Nicole McMillian, Jillian Scavone
Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28040720/myelodysplastic-syndromes-version-2-2017-nccn-clinical-practice-guidelines-in-oncology
#12
Peter L Greenberg, Richard M Stone, Aref Al-Kali, Stefan K Barta, Rafael Bejar, John M Bennett, Hetty Carraway, Carlos M De Castro, H Joachim Deeg, Amy E DeZern, Amir T Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A Griffiths, David Head, Ruth Horsfall, Robert A Johnson, Mark Juckett, Virginia M Klimek, Rami Komrokji, Lisa A Kujawski, Lori J Maness, Margaret R O'Donnell, Daniel A Pollyea, Paul J Shami, Brady L Stein, Alison R Walker, Peter Westervelt, Amer Zeidan, Dorothy A Shead, Courtney Smith
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28040716/nccn-guidelines-insights-genetic-familial-high-risk-assessment-breast-and-ovarian-version-2-2017
#13
Mary B Daly, Robert Pilarski, Michael Berry, Saundra S Buys, Meagan Farmer, Susan Friedman, Judy E Garber, Noah D Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K Litton, Lisa Madlensky, Sofia D Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C Voian, Jeffrey N Weitzel, Myra J Wick, Georgia L Wiesner, Mary Dwyer, Susan Darlow
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28039695/docetaxel-in-the-treatment-of-castrate-resistant-advanced-prostate-cancer-a-paradigm-in-change
#14
Mircea Dediu, Florentina Bratu, Mihaela Amarandei, Eniko Fejer
Until last year, the international guidelines recommended the use of docetaxel in advanced prostate cancer (PC) at the time of progression following androgen deprivation therapy (ADT). Nevertheless, two randomized phase III trials, CHAARTED and STAMPEDE, delivered level I evidence showing that upfront introduction of docetaxel, during the androgen sensitive course of disease, is able to significantly improve the patients' overall survival. As such, this strategy was rapidly included in the current guideline recommendations, with slightly different indications in the ESMO as compared to the NCCN version...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28024648/extent-of-lymphadenectomy-is-associated-with-improved-overall-survival-after-esophagectomy-with-or-without-induction%C3%A2-therapy
#15
Pamela Samson, Varun Puri, Stephen Broderick, G Alexander Patterson, Bryan Meyers, Traves Crabtree
BACKGROUND: National Comprehensive Cancer Network (NCCN) guidelines recommend sampling 15 or more lymph nodes during esophagectomy. The proportion of patients meeting this guideline is unknown, as is its influence on overall survival (OS). METHODS: Univariate analysis and logistic regression were performed to identify variables associated with sampling 15 or more lymph nodes among patients undergoing esophagectomy in the National Cancer Data Base (NCDB). The NCCN guideline was evaluated in Cox proportional hazards modeling, along with alternative lymph node thresholds...
December 23, 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28017807/lymphadenectomy-with-optimum-of-29-lymph-nodes-retrieved-associated-with-improved-survival-in-advanced-gastric-cancer-a-25-000-patient-international-database-study
#16
Yanghee Woo, Bryan Goldner, Philip Ituarte, Byrne Lee, Laleh Melstrom, Taeil Son, Sung Hoon Noh, Yuman Fong, Woo Jin Hyung
BACKGROUND: Gastric adenocarcinoma is an aggressive disease with frequent lymph node(LN) metastases for which lymphadenectomy results in a survival benefit. In the United States, the NCCN guidelines recommend D2 lymphadenectomy or a minimum of 15 LNs retrieved. However, retrieval of only 15 LNs is considered by most international guidelines as inadequate. We seek to evaluate the survival benefits associated with a more complete lymphadenectomy. STUDY DESIGN: An international database was constructed by combining gastric cancer cases from the SEER database (n=13,932) and the Yonsei University Gastric Cancer database (n=11,358)(total n=25,289)...
December 22, 2016: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/27989612/psychological-stress-in-geriatric-patients-with-genito-urinary-cancers
#17
Désirée Louise Dräger, Chris Protzel, Oliver W Hakenberg
BACKGROUND: Two-thirds of all cancer cases affect patients who are older than 65years, yet the specific conditions of the treatment and supportive care in this age group are poorly studied. There are limited data on the specific psycho-oncological problems in elderly patients with genito-urinary cancers. The aim of this study was to investigate the psychosocial needs of elderly patients with genito-urinary tumors using screening questionnaires and to use such screening questionnaires for an in-patient psychosocial treatment program...
December 15, 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/27989216/the-safety-of-talimogene-laherparepvec-for-the-treatment-of-advanced-melanoma
#18
Alexandra Gangi, Jonathan S Zager
Talimogene laherparepvec (T-VEC, IMLYGIC) is an oncolytic herpes virus type I used as intralesional therapy for the treatment of unresectable metastatic melanoma in a cutaneous, subcutaneous, or nodal location. Talimogene laherparepvec selectively replicates within and lyses tumor cells while producing granulocyte macrophage colony-stimulating factor (GM-CSF), which may promote an immune mediated antitumor response. Areas covered: The US Food and Drug Administration approved Talimogene laherparepvec in late 2015 following the completion of phase I, II and III trials that demonstrated safety and efficacy...
December 28, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27987243/ahns-series-do-you-know-your-guidelines-principles-of-surgery-for-head-and-neck-cancer-a-review-of-the-national-comprehensive-cancer-network-guidelines
#19
Matthew C Miller, David Goldenberg
This article continues a series developed by the American Head and Neck Society's Education Committee entitled "Do you know your guidelines?" It is hoped that these features will increase awareness of and adherence to current best practices in head and neck cancer care. In this installment, the National Comprehensive Cancer Network (NCCN) guidelines for surgical therapy are reviewed. © 2016 Wiley Periodicals, Inc. Head Neck, 2016.
December 16, 2016: Head & Neck
https://www.readbyqxmd.com/read/27987030/improved-decision-making-in-intermediate-risk-prostate-cancer-a-multicenter-study-on-pathologic-and-oncologic-outcomes-after-radical-prostatectomy
#20
Jean Baptiste Beauval, Guillaume Ploussard, Bastien Cabarrou, Mathieu Roumiguié, Adil Ouzzane, Jérome Gas, Annabelle Goujon, Gautier Marcq, Romain Mathieu, Sébastien Vincendeau, Xavier Cathelineau, Pierre Mongiat-Artus, Laurent Salomon, Michel Soulié, Arnaud Méjean, Alexandre de La Taille, Morgan Rouprêt, François Rozet
BACKGROUND: Prognoses for intermediate-risk prostate cancer (PCa) remain heterogeneous. Improved substratification could optimize treatment and monitoring strategies. The objective was to validate this subclassification in a radical prostatectomy (RP) series. METHODS: Between 2000 and 2011, 4038 patients who underwent RP for intermediate-risk PCa in seven French academic centers were included. Unfavorable intermediate-risk (UIR) PCa was defined as having a primary Gleason score of 4, ≥50% positive biopsy cores (PPBC), or more than one D'Amico intermediate-risk factor (i...
December 16, 2016: World Journal of Urology
keyword
keyword
30821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"